EMEA-001776-PIP02-17-M01
Key facts
| Invented name |
Skyrizi
|
| Active substance |
Risankizumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0039/2021
|
| PIP number |
EMEA-001776-PIP02-17-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|